Authorized purpose: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.
Clinical role
Cardiac-image calculation, quantification, visualization, preliminary segmentation, and interoperability support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Heart; myocardial scar and cardiac structures
Key limitation
Keep in mind: Image quality and resolution determine the accuracy of produced data; results require qualified professional review, are not irrefutable medical advice, and clinical significance for arrhythmia-substrate identification or risk stratification is not established.
FDA K253969 indication, page 4: cardiac calculation, quantification and visualization. Radiotherapy planning is explicitly excluded; RTSTRUCT is an interoperability output.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.
Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Heart; myocardial scar and cardiac structures Input: Supported cardiac CT and MR DICOM images, including CTA and specified cardiac MR sequences.
Who uses it?Intended users: Qualified cardiologists, electrophysiologists, radiologists, and trained technicians.
What does the software produce?Output: Cardiac structure segmentations, measurements, visualizations, preliminary contours, and DICOM RT Structure Set exports.
What is its most important limitation?Key limitation: Image quality and resolution determine the accuracy of produced data; results require qualified professional review, are not irrefutable medical advice, and clinical significance for arrhythmia-substrate identification or risk stratification is not established.
Clinical takeaway. Clinical role: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-inferiority performance testing (predefined margin) of each machine learning feature on a subset of the DICOM dataset, with each testing dataset from hospitals not used in algorithm development. Ground truth was annotated by two clinical experts independent of the training-data experts; acceptance metrics included mean surface distance and Hausdorff distance. The document states that some tests did not meet the non-inferiority criteria, with sub-pixel discrepancies. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.
Image quality and resolution determine the accuracy of produced data; results require qualified professional review, are not irrefutable medical advice, and clinical significance for arrhythmia-substrate identification or risk stratification is not established.
The exact FDA document reports non-inferiority performance testing (predefined margin) of each machine learning feature on a subset of the DICOM dataset, with each testing dataset from hospitals not used in algorithm development. Ground truth was annotated by two clinical experts independent of the training-data experts; acceptance metrics included mean surface distance and Hausdorff distance. The document states that some tests did not meet the non-inferiority criteria, with sub-pixel discrepancies. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The performance testing for each machine learning feature was performed using a subset of the initial DICOM dataset," … "Each testing dataset has been selected from hospitals not used in any stage of algorithm development, including training.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports non-inferiority performance testing (predefined margin) of each machine learning feature on a subset of the DICOM dataset, with each testing dataset from hospitals not used in algorithm development. Ground truth was annotated by two clinical experts independent of the training-data experts; acceptance metrics included mean surface distance and Hausdorff distance. The document states that some tests did not meet the non-inferiority criteria, with sub-pixel discrepancies. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The performance testing for each machine learning feature was performed using a subset of the initial DICOM dataset," … "Each testing dataset has been selected from hospitals not used in any stage of algorithm development, including training.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Representative cardiac structure testing dataset
100 cases
EndpointFeature-specific machine-learning performance-test case count
PopulationSelected 3D CTA feature testing datasets from U.S. and outside-U.S. hospitals
Tested versionADAS 3D version 1.4 configuration described in K253969
DesignFDA 510(k) machine-learning verification and performance testing with feature-specific DICOM datasets selected from hospitals not used for algorithm development.
PopulationHeart; myocardial scar and cardiac structures
Scopeexact submission
Tested versionADAS 3D version 1.4 configuration described in K253969
IndependenceSponsor or vendor study
K253969
The FDA summary reports feature-specific case counts and distance, Dice, shift, and color-agreement metrics; a single case-count metric is promoted here without generalizing across features.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K253969 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported cardiac CT and MR DICOM images, including CTA and specified cardiac MR sequences.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes CT and MR DICOM inputs and DICOM RT Structure Set export solely for interoperability and standardized exchange of anatomical contour information.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Cardiac structure segmentations, measurements, visualizations, preliminary contours, and DICOM RT Structure Set exports.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Cardiac structure segmentations, measurements, visualizations, preliminary contours, and DICOM RT Structure Set exports.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes CT and MR DICOM inputs and DICOM RT Structure Set export solely for interoperability and standardized exchange of anatomical contour information.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Only qualified cardiologists, electrophysiologists, radiologists, and trained technicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K253969 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Image quality and resolution determine the accuracy of produced data; results require qualified professional review, are not irrefutable medical advice, and clinical significance for arrhythmia-substrate identification or risk stratification is not established.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The FDA package describes CT and MR DICOM inputs and DICOM RT Structure Set export solely for interoperability and standardized exchange of anatomical contour information.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Image quality and resolution determine the accuracy of produced data; results require qualified professional review, are not irrefutable medical advice, and clinical significance for arrhythmia-substrate identification or risk stratification is not established.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K253969 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Image quality and resolution determine the accuracy of produced data; results require qualified professional review, are not irrefutable medical advice, and clinical significance for arrhythmia-substrate identification or risk stratification is not established.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. cardiac CT and MR image-analysis software limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
12Source classes checked
20Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads
Twenty PubMed records and six trial records were screened. Many reference ADAS 3D, ADAS 3D LV, or another cardiac post-processing platform, but none identifies ADAS 3D version 1.4 from K253969; all 26 records are quarantined and none is promoted. The current discovery snapshot contains 20 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: MI View&GO is a medical diagnostic application for viewing, manipulating, quantifying, analyzing, and comparing PET, nuclear-medicine, CT, and MR images across one or more time points, including labeled oncology, cardiology, neurology, organ-function, and radiotherapy-planning workflows.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Whole body, organs, tumors, heart, brain, and oncology regions
Authorized purpose: Imagine Enterprise Suite receives, stores, shares, visualizes, quantifies, and processes images from multiple modalities; MPXA-2000 supports coronary-angiography calculation with automated vessel contours that require review and editing.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Cardiac and coronary anatomy plus multi-modality clinical studies
3mensio Workstation is standalone medical-image analysis software for advanced visualization and quantitative analysis of cardiovascular structures. It supports CT, X-ray angiography, and two- and three-dimensional ultrasound DICOM data for planning and sizing cardiovascular interventions, postoperative evaluation, coronary measurements, and calcium scoring.
Modality
Radiological images; modality varies or is not specified in FDA list
Authorized purpose: syngo Dynamics VA41D is a multimodality, vendor-agnostic cardiology image and information system for management, processing, review, post-processing, and quantification of cardiac ultrasound, X-ray angiography, nuclear medicine, CT, MR, vascular ultrasound, and obstetric or fetal studies.
Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Cardiac, vascular, obstetric, and fetal anatomy represented in multimodality studies
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.